A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) With Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT04460937

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:27:37.416970+00:00

Published At

2025-06-08T00:00:00+00:00

Record Updated At

2025-07-08

Results Posted At

2025-06-08

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Distal Esophagus Adenocarcinoma", "Gastric Cardia Adenocarcinoma", "Metastatic Esophageal Adenocarcinoma", "Metastatic Esophageal Squamous Cell Carcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Malignant Neoplasm in the Leptomeninges", "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Unresectable Esophageal Adenocarcinoma", "Unresectable Esophageal Carcinoma", "Unresectable Esophageal Squamous Cell Carcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2025-07-08"

protocolSection.identificationModule.nctId

"NCT04460937"

protocolSection.identificationModule.officialTitle

"A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) With Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

"2025-06-08"

Study condition terms

• Clinical Stage III Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Distal Esophagus Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Gastric Cardia Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Esophageal Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Esophageal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Gastroesophageal Junction Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Malignant Neoplasm in the Brain (protocolSection.conditionsModule.conditions)
• Metastatic Malignant Neoplasm in the Leptomeninges (protocolSection.conditionsModule.conditions)
• Pathologic Stage III Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Unresectable Esophageal Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Unresectable Esophageal Carcinoma (protocolSection.conditionsModule.conditions)
• Unresectable Esophageal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
• Unresectable Gastroesophageal Junction Adenocarcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.